Silexion Therapeutics Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
42.0%projected annual EPS growth
Analyst Coverage
2analysts covering
FY EPS (est.)
-$53.10next fiscal year
Monitoring Framework
Key Performance Indicators
Clinical Trial Initiation of SIL204 QuarterlyTarget: Initiation of Phase 2/3 clinical trial in LAPC patients
Regulatory Approvals for European Sites QuarterlyTarget: Approval of Clinical Trial Application (CTA) by Germany's BfArM
Shareholders' Equity Compliance Quarterly2.6MTarget: Maintain above $2.5 million Nasdaq minimum requirement
Watch Items
- Nasdaq Minimum Bid Price ComplianceTrigger: Share price below $1.00 for 30 consecutive business daysAction: Monitor post-reverse split trading and execute further corporate actions if necessary to maintain listing
- Shareholder Vote on Capital ProposalsTrigger: Extraordinary General Meeting on July 13, 2026Action: Obtain approval for warrant exercisability and authorized share capital increase to secure future funding
- SIL204 Phase 2/3 Safety Run-in DataTrigger: Completion of safety run-in cohort of approximately 18 patientsAction: Review safety profile and prepare for expansion into the randomized cohort of 166 patients
Research as of 20 Jun 2026